Argenx Se (ARGX) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Argenx Se  (NASDAQ: ARGX)


Argenx Se's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Argenx Se's ROA in the fourth quarter of 2025?
Argenx Se achieved a return on average assets (ROA) of 15.56 % in its fourth quarter of 2025, this is above ARGX's average return on assets of -8.12%.
Argenx Ses assets during the 12 months ending in the fourth quarter of 2025 are valued at $8 billion

ROA has improved compared to 10.38% in the third quarter of 2025, due to net income growth.

However, within the Healthcare sector 72 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 403.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Total Assets Change 14.75 % 39.99 % 12.65 % 39.99 % 41.26 %
Y / Y Net Income Change 55.1 % - - - -
Net Income (TTM) in million 1,292 833 833 833 833
Return On Assets (TTM) 15.56 % 10.38 % 11.25 % 11.56 % 12.65 %
ARGX's Total Ranking # 403 # # # # 472
Total Assets (TTM) in million 8,683 8,683 7,176 8,683 7,567
Seq. Total Assets Change 0 % 21 % -17.36 % 14.75 % 21.99 %
Seq. Net Income Change - - - - -

ARGX's 5 Years Annual ROA >> Back to ARGX Management Effectiveness >> Compare ARGX ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 12
Sector # 73
Overall # 397

Return On Assets Statistics
High Average Low
14.88 %
-8.12 %
-26.69 %
(Dec 31 2025)   (Dec 31 2020)





Financial Statements
Argenx Se's Assets $ 8,683 million ARGX's Balance sheet
Argenx Se's Income $ 1,292 million Quarterly ARGX's Income Statement
ARGX's Income by Division See ARGX's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 43.61 % 41.26 % 43.31 % 24.8 % 32.9 %
Total Assets in million 10,866 7,567 5,357 3,738 2,995
Y / Y Net Income Change 55.1 % - - - -
Net Income in million 1,292 833 -295 -710 -408
Annual Return On Assets 11.89 % 11.01 % -5.51 % -18.98 % -13.63 %

ARGX's 5 Years Annual ROA >> Back to ARGX Management Effectiveness >> Compare ARGX ROA to its Competitors



Comment on ARGX's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 11.89 % compared to prior year, due to annual net income growth of 55.1 % to $1,292.04 million, while value of Argenx Se's overall assets grew just by 43.61 % to $10,865.91 million, compared to $10,865.91 a year before.


More Return On Assets Ratios
ARGX's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ARGX's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ARGX's Competitors
Subscribers only: Roa for Argenx Se's Suppliers
Subscribers only: Return On Assets for ARGX's Customers

You may also want to know
ARGX's Roi ARGX's Inventory Turnover Ratio ARGX's Growth Rates ARGX's Dividend Comparisons
ARGX's Profitability Ratios ARGX's Asset Turnover Ratio ARGX's Dividend Growth
ARGX's Roe ARGX's Valuation Ratios ARGX's Financial Strength Ratios ARGX's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector ROA
Coherus Oncology inc   42.39 %
Elite Pharmaceuticals Inc   41.21 %
Alpha Tau Medical Ltd  40.35 %
Galmed Pharmaceuticals Ltd   37.04 %
Dariohealth Corp   36.94 %
Abeona Therapeutics Inc   35.76 %
Novavax inc   35.32 %
Medinotec Inc   34.18 %
Zevra Therapeutics Inc   33.84 %
Oramed Pharmaceuticals Inc  33.67 %
Idexx Laboratories Inc  31.91 %
Acadia Pharmaceuticals Inc   29.77 %
Newgenivf Group Limited  29.73 %
Hutchmed china Limited  26.11 %
Petros Pharmaceuticals inc   26.04 %
Adma Biologics Inc   25.98 %
Theravance Biopharma inc   25.35 %
Ptc Therapeutics inc   25.21 %
Qhslab Inc   25.12 %
Medpace Holdings Inc   25.07 %
Mettler toledo International Inc   25.07 %
Compugen Ltd  22.57 %
Lifemd Inc   21.39 %
Catalyst Pharmaceuticals Inc   21.24 %
Iradimed Corporation  20.83 %
Incyte Corporation  20.70 %
Transmedics Group Inc   20.34 %
Eli Lilly And Company  19.76 %
Innoviva Inc   19.19 %
Novo Nordisk A  18.87 %

Date modified: 2026-07-07T09:15:04+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.